Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
Tesla Launches New Model Y Variant in the US Starting at $41,990 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
BRISBANE, Calif., May 31, 2017 -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced today that Cameron Durrant, MD, chairman and CEO, will present a company overview at two investor conferences in early June.
Details of the presentations follow:
Primary Capital, The Investor Conference
Date: Sunday, June 4, 2017
Location: The Resort at Pelican Hill, Newport Beach, Calif.
7th Annual LD Micro Invitational
Date: Tuesday, June 6, 2017, 1:30 p.m. PT
Track: 5
Location: Luxe Sunset Boulevard Hotel, Los Angeles, Calif.
In addition, senior management will hold one-on-one meetings at the conferences. To schedule a meeting, contact MZ Group at [email protected].
About KaloBios Pharmaceuticals, Inc.
KaloBios Pharmaceuticals, Inc. (OTC:KBIO) is an emerging biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative and responsible business models. Lead compounds in the KaloBios portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab. Lenzilumab has potential for treatment of various rare diseases, including hematologic cancers such as chronic myelomonocytic leukemia (CMML) and potentially juvenile myelomonocytic leukemia (JMML). For more information, visit www.kalobios.com.
CONTACT: Investors: Mike Cole O: 949-259-4988 C: 949-444-1341 [email protected] Media: Lisa Guiterman O: 301-217-9353 C: 202-330-3431 [email protected]
